EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Part of paid clinical trials in Newport Beach, California.

Sponsor
Mediar Therapeutics
Study ID
NCT07287670
Phase
PHASE2
Status
Recruiting

Conditions

  • Diffuse Cutaneous Systemic Sclerosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MTX-474 — BIOLOGICAL
    Dosage level: 4 mg/kg Unit dose strength: 50mg/ml MTX-474 is a human immunoglobulin G1 (IgG1) monoclonal antibody that binds the human EphrinB2 with high specificity and high affinity. MTX-474 is being developed as a therapy for patients with systemic sclerosis (SSc).
  • Placebo — OTHER
    Placebo

Study Details

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Key Dates

Start date
Apr 16, 2026
Status verified
Apr 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
85 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: MTX-474
    MTX-474
  • Placebo Comparator: Placebo
    Placebo

Primary Outcome Measure

Change from baseline in Modified Rodnan Skin Score (mRSS) [ Time Frame: Baseline to week 24 ]

Central Contacts

Locations (6)

FacilityCityStateZIPSite coordinators
EncompaSSc site in Newport Beach, CA 92663Newport BeachCalifornia92663
EncompaSSc contact
617 802 6568
EncompaSSc site in Clearwater, FL 33765ClearwaterFlorida33765
EncompaSSc contact
617 802 6568
EncompaSSc site in Tampa, FLTampaFlorida33606
EncompaSSc contact
617 802 6568
EncompaSSc site in Baltimore, MDBaltimoreMaryland21224
EncompaSSc contact
617 802 6568
EncompaSSc site in Boston, MABostonMassachusetts02118
EncompaSSc contact
617 802 6568
EncompaSSc site in Dallas, TXDallasTexas75246
EncompaSSc contact
617-802-6568

Find similar trials in Newport Beach, CA

Related Studies